Triple Agonists: The Next Big Thing in GLP-1 & Metabolic Medicine?

In this episode of Hormones and Hope, Dr. Chhaya Makhija breaks down one of the most rapidly evolving areas of modern medicine: GLP-1 receptor agonists.With new medications, expanding FDA approvals, and growing conversations about weight loss, diabetes, longevity, and metabolic health, it can be difficult to separate evidence-based science from social media hype. Dr. Makhija explains the differences between semaglutide, tirzepatide, and the highly anticipated triple agonist retatrutide while helping listeners understand what we know today—and what remains under investigation.She also discusses why personalized care matters when prescribing GLP-1 medications, how these therapies may impact long-term health beyond weight loss, and why patients should be cautious about compounded or unapproved versions of emerging drugs.Whether you're currently taking a GLP-1 medication, considering one, or simply curious about the future of metabolic medicine, this episode provides a practical, science-backed overview of where the field stands in 2026.Sign Up for The M3 Masterclass with Dr.  Makhija:https://zoom.us/meeting/register/llQXKQSGRCKVpZBMHoqb2A#/Download the Free Guide 'Your Health on GLP-1' Here:https://dr-chhaya.myflodesk.com/glp1Follow Dr. Chhaya Makhija here:https://www.instagram.com/chhayamakhijamd/https://www.facebook.com/unifiedendocrinehttps://unifiedendocrinecare.com/https://www.youtube.com/@chhayamakhijamdhttps://www.linkedin.com/in/chhayamakhijamd/Email: [email protected]: This podcast is for educational, informational, and entertainment purposes only. It’s not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider for personalized guidance.🔔 Don’t forget to like, subscribe, and hit the bell icon!